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In classical myeloproliferative disorders (MPDs) induced by JAK2V617F, JAK2 exon 12 or MPL W515 mutations, constitutive activation of the Janus kinase/Signal transducer and activator of transcription (JAK/STAT) pathway may confer cytokine hypersensitivity and cytokine-independent growth. In vitro and animal model studies have shown that JAK2V617F may be sufficient to explain the onset of some MPDs such as polycythemia vera (PV). However, phenotypic heterogeneity observed between the classical MPDs may result from an additional increase in JAK/STAT signaling. We hypothesized that alterations in the regulators of JAK2 activity, such as the suppressor of cytokine signaling (SOCS) proteins, may contribute to MPD in addition to JAK2 or MPL mutations. 1 The SOCS proteins are potent inhibitors of JAK2 signaling. 2 It has been established that SOCS1, SOCS2 and SOCS3 promoters are hypermethylated, thus underexpressed in primary myelofibrosis (PMF). 1, 3, 4 We earlier reported that SOCS1 overexpression inhibits spontaneous megakaryocytic growth in PMF, 5 but the SOCS1 promoter methylation status in PV compared with PMF presents no difference, suggesting that changes in its expression do not explain MPD heterogeneity. 3 In contrast, Fourouclas et al. 6 have shown that SOCS3 is hypermethylated in a subset of PMFs, but not in other MPDs. Thus, we investigated the role of SOCS3 promoter hypermethylation in PMF. Our results establish that SOCS3 downregulates thrombopoietin (TPO) induced JAK2 signaling, but has no effect on PMF megakaryocyte spontaneous growth.
Sample cells were obtained after written informed consent, in accordance with the Declaration of Helsinki Principles. CD34 þ cells (495%) were enriched by positive selection and cultured in a serum-free medium supplemented with growth factors as described earlier. 7 RNAs were extracted from purified neutrophils, platelets and CD34 þ cells treated or not with 1 mM of the DNA hypomethylation agent, 5-azacytidine, for 2 days, and analyzed for the SOCS3 expression using reverse transcription (RT) real-time PCR. In parallel, JAK2 allele dosage was determined using real-time PCR as described earlier. 7 Methylation of SOCS3 promoter in granulocyte DNA samples was assessed as described earlier. 8 We performed transduction of UT7 11oc1 cell line and PMF (n ¼ 5) and normal (n ¼ 5) CD34 þ cells with empty pRRL EF1a Figure 1 Downregulation of SOCS3 expression in primary myelofibrosis is regulated by promoter methylation. SOCS3 mRNA expression was assessed in (a) granulocytes and in (b) platelets. Each open circle represents one patient analysis using RT-qPCR. The horizontal trace marks the median value. PV, polycythemia vera; ET, essential thrombocythemia; PMF, primary myelofibrosis. We isolated RNA from granulocytes PMF samples (n ¼ 21) (10 JAK2V617F-positive PMFs, 2 MPLW515L-and K-positive PMFs and 9 JAK2-and MPL-negative PMFs) 10 JAK2V617F-postive PV samples and 10 ET samples (5 with the JAK2V617F mutation and 5 without mutation). Platelets were obtained from 16 PMF samples (7 JAK2V617F-positive PMFs, 1 MPLW515L-positive and 8 JAK2-and MPL-negative PMFs) 22 JAK2V617F-positive PV samples and 30 ET samples (9 with the JAK2V617F mutation, 5 with MPL515 mutations and 16 without mutation). Values at the bottom of the two graphs indicate the number of patients within each group. The P-values (t-test) show significant differences between groups. (c) Correlation between the expression of SOCS3 and the ratio of JAK2V617F/JAK2WT in ET and PV patients. (d) Methylation analysis of SOCS3 CpG islands by sequencing PCR products from five low SOCS3 PMFs, five normal SOCS3 PMFs, seven ET and four controls. We analyzed 45 methylated sites within the SOCS3 promoter region (À711 to À204). Non-CpG cytosine residues are shown in open circles (converted to 'T' in bisulfite-modified DNA), whereas CpG cytosine residues are shown in black circles (remaining as 'C' in bisulfite-modified methylated CpG dinucleotides). Only PMF patients showed methylation in part of examined CpG dinucleotides. PMF and control CD34 þ cells were treated by the 5-azacytidine hypomethylating agent for 2 days in serum-free medium supplemented with EPO, TPO, IL-3 and SCF. We studied (e) SOCS3 and (f) JAK2 expressions by RT-qPCR. Histograms represent the ratio with/without hypomethylating treatment of SOCS3 or JAK2 expression.
Letters to the Editor or pRRL EF1a SOCS3 VSV-G-pseudotyped lentiviral vector, as described earlier. 9 determinant in explaining the phenotypic differences observed between MPDs harboring a same oncogenic event. SOCS3 promoter has been shown to be hypermethylated specifically in PMF relative to other MPDs. We first examined the levels of SOCS3 expression in PMF, PV and essential thrombocythemia (ET) cell samples. PMF, when compared with PV and control platelets and granulocytes, harbored a significant reduction in SOCS3 RNA expression (Figures 1a and b) . There was no correlation between the expressions of SOCS3 and JAK2V617F in neither PMF nor ET patients. However, in JAK2V617F-positive PV and ET samples only, we identified a correlation between the ratio of JAK2V617F/JAK2WT and SOCS3 expression. In PV and ET, SOCS3 was upregulated with increasing expression of the JAK2V617F allele in platelets ( Figure 1c ). It is possible that the overactivation of the JAK/STAT signaling pathway, resulting from JAK2V617F constitutive activation, might be directly responsible for the increase in SOCS3 expression. However, SOCS3 was downregulated in JAK2V617F-positive PMF samples. Thus, we hypothesized that the decrease in SOCS3 expression in PMF could be a consequence of SOCS3 gene or promoter a b methylation. Indeed, at least 4 out of 45 CpG islands in the SOCS3 promoter (promoter region is À711 to À204 8 ) were methylated in the five studied downexpressing SOCS3 PMF samples (4, 12, 19 , 23 and 31 methylated CpG sites) (Figure 1d ). The SOCS3 promoter was not methylated in other tested ET and control samples (Figure 1d ). However, some other sites of methylation exist in SOCS3 gene, rendering the conclusion of a direct correlation between promoter methylation and RNA expression difficult to make. 10 To clearly show that methylation, independently of the methylated sites, was responsible for the decrease in SOCS3 expression, PMF CD34 þ cells were treated by the 5-azacytidine hypomethylating agent. We observed a two-to three-fold increase in SOCS3 expression only in the hypomethylated PMF samples (Figure 1e ), but there was no change in JAK2 expression known to be independent of regulation by epigenetic processes (Figure 1f) .
To determine whether SOCS3 methylation may be a secondary oncogenic event that cooperates with JAK2V617F or MPL W515 mutations in spontaneous cell growth, we overexpressed SOCS3 in PMF CD34 þ cells and in the human erythro-megakaryocytic UT7 11oc1 cell line using a lentiviral strategy. There was a 3-fold increase in SOCS3 protein level in the cell line ( Figure 2a ) and a 1.5-fold increase in cultured megakaryocytes (data not shown) when compared with similar cells transduced with the empty vector. We observed an inhibition of TPO-induced JAK2, STAT5, STAT3, AKT and ERK phosphorylations in the cell line (Figure 2b ). These results show that SOCS3 inhibits TPO signaling in a JAK2 wild-type context.
Moreover, SOCS3 overexpression in normal CD34
þ cells reduced their cloning capacity by 50% in the presence of TPO (Figure 2c) showing the role of SOCS3 as a negative regulator of TPO-induced proliferation in primary cells. Similar results were observed for PMF-derived cells after TPO stimulation (Figure 2d ). Oncogenic events, such as JAK2V617F and MPLW515 mutations, confer cytokine-independent differentiation of CD34 þ cells into megakaryocytes. Moreover, chemical JAK2 inhibitor AG490 and SOCS1 overexpression inhibit the megakaryocytic spontaneous growth. 5 Thus, it is surprising that SOCS3 overexpression had no effect on the spontaneous growth of PMF megakaryocytes, independently of their first oncogenic event (that is JAK2V617F or MPL W515 mutations) (Figure 2e ) These results establish that SOCS3 does not reduce the spontaneous cell proliferation in a JAK2V617F or a MPLW515 mutation background. This is in agreement with Hookham et al. 11 results showing that SOCS3 did not inhibit JAK2V617F signaling. As a matter of fact, Mesa et al. 12 have shown that the 5-azacytidine hypomethylating agent has limited therapeutic activity in PMF.
Understanding how a single oncogenic event such as JAK2V617F or MPL W515 mutations may trigger several disorders with different prognosis remains one of the most important questions in MPD physiopathology. The hypothesis of the JAK2V617F allele burden (the zygoty increases with MPD severity) has been validated by mouse models and the studies of patients. Post-PV myelofibrosis has a higher JAK2V617F allele burden than PV, suggesting that myelofibrosis is the consequence of the homozygous JAK2V617F clone. In contrast, in JAK2V617F PMF, the JAK2V617F allele burden is identical or even lower than in PV, suggesting the presence of a secondary (or preexisting) event responsible for disease development. The presence of pre-JAK2V617F genetic lesions in some ETs and constitutive genetic polymorphism differences between MPDs has been reported. Secondary genetic lesions seem to be more frequent in PMF than in other classical MPDs. The methylation of SOCS3 promoter in PMF may be relevant to the pathogenesis: in fact, only part of the megakaryocyte proliferation may be favored by the growth independency. Indeed in this disorder, the megakaryocyte hyperplasia is probably dependent on TPO, as the cell surface MPL level on platelets and megakaryocytes is decreased leading to increased TPO levels for the same mass of megakaryocytes and platelets. Thus, SOCS3 downregulation may increase megakaryocyte proliferation, amplifying defect in the megakaryocyte differentiation in the case where it would be related to the level of cytokine signaling. One hypothesis is that SOCS3 is not involved in the regulation of JAK2V617F or active MPL mutant-dependent proliferation, in the absence of TPO, suggesting that it may exist differences in signaling between the constitutively active and the ligand-stimulated status.
Our experiments have shown that (i) epigenetic events are confirmed in PMF cells; (ii) SOCS3 promoter is methylated in at least part of PMFs and independently of their first oncogenic event; and (iii) SOCS3 inhibits TPO-induced megakaryocytic proliferation in normal and PMF but not the spontaneous growth in PMF. Several lymphoma-and leukaemia-associated chromosomal translocations are present in the peripheral blood of healthy individuals (HI). Translocation t(14;18), the genetic hallmark of follicular lymphoma (FL) that juxtaposes the BCL2 protooncogene near the immunoglobulin heavy chain (IGH) locus, can be detected in most HI at highly variable frequency. 1 Individual characteristics, such as smoking habits, viral infection, and occupational and/or environmental factors (such as pesticide exposure), suspected to play a role in lymphoma genesis, have been associated with an increase in t(14;18) translocation frequency. 2 We recently showed that clonotypic t(14;18)-positive cells can persist in the peripheral blood over a long period of time. 3 High t(14;18) rates in HI are mainly because of an expanding population of atypical B cells issued from germinal centre that share genotypic and phenotypic features with FL cells. 4 t(14;18)-positive cells in HI may thus represent much more advanced precursors of the FL pathway than thought earlier.
As t(14;18) in FL, translocation t(11;14)(q13;q32) is considered as the primary event in the pathogenesis of mantle cell lymphoma (MCL), a neoplasia that accounts for 5-10% of all non-Hodgkin's lymphoma. 5 The juxtaposition of the immunoglobulin heavy chain joining region on chromosome 14 to a chromosomal locus on 11q13 places the CCND1/BCL1 gene under the control of the IGH enhancer, resulting in aberrant overexpression of cyclin D1, a positive regulator of the cell cycle. 5 Both t(11;14) and t(14;18) translocations are thought to arise from the same mechanism of illegitimate repair of V(D)J recombination intermediates, with recombinase-mediated breaks in the IGH locus and double-stranded breaks of different origins at the oncogene loci. 6 Considering mechanistic and oncogenic similarities between t(14;18) and t(11;14), we sought to evaluate the incidence of t(11;14) in HI and their persistence over time. To date, the presence of t(11;14)-positive cells in peripheral blood from HI has only been reported in one individual over the hundred HI studied and at a relatively low frequency (Bsix copies in 1 million normal cells). 7 In this paper, we used a sensitive fluctuation nested PCR analysis to determine the prevalence, frequency and long-term evolution of circulating t(11;14)-positive cells in the peripheral blood of 71 healthy males who had been examined earlier for the t(14;18) translocation using a similar approach.
2,3 Twenty eight individuals, who were not exposed to pesticides, were issued from a cohort of hospital and laboratory workers and were defined as reference population (mean age at enrolment: 41, min-max: 25-56). 3 Forty three farmers (median age at enrolment: 43, min-max: 27-59) from the EPIBIO97 agricultural cohort, defined as never smoking males and pesticide users on crops at enrolment, were also included. 2 Briefly, fluctuation nested PCR assay was performed on DNA extracted from peripheral blood mononuclear cells (PBMNC) to amplify the IGH/CCND1 der(14) breakpoint (30 replicates per sample) with primers surrounding the BCL1-Major Translocation Cluster (MTC) in combination with JH consensus primers from the IGH locus, and the frequency was estimated using a Poisson's model, as described earlier. 2, 8 The sensitivity of our assay allows us to detect, as few as, one t(11;14)-positive cell in a background of 600 000 normal cells. Sequencing of all PCR products was performed and compared with the GenBank database using BLAST program to identify the CCND1/IGH breakpoint positions and the intervening N region.
For five individuals, two from the reference population (7%) and three farmers (7%), PBMNC samples obtained at enrolment were positive for t (11;14) . Frequencies were at 0.8 and 1.7 translocation copies/10 6 PBMNC (Table 1) . For comparison, the prevalence of t(14;18)-positive individuals, determined from the same blood samples, was 53% among the reference population (median frequency: 0.6 Â 10 ). Long-term evolution of t(11;14) could be followed in four HI. t(11;14)-positive PBMNC remained detectable in blood sample up to 9 years after the initial sampling. Frequency varied inside the range of uncertainty in one individual from the reference population and in one farmer, but underwent a threefold and 10-fold increase in the other farmers, reaching 1.7 Â 10 -5 in farmer F272 (Table 1) . Individual R99, for whom four blood samples obtained at intervals of 2-3 years were available, was also included in the follow-up. He was negative at enrolment and 3 years later, whereas t(11;14)-positive cells became detectable in PBMNC obtained at the two latter sampling periods.
All the translocation fragments amplified from the t(11;14)-positive individuals were sequenced (Table 1) . N-nucleotides were present in every case and ranged from 1 to 27 bp in length. Each individual was unique with regard to BCL1 breakpoint, N-nucleotides and J H breakpoint, assuring that no false positive was present. Remarkably, analysis of CCND1/J H junctions showed that the same t(11;14)-positive clone persisted over
